The Children's Hospital of Philadelphia

Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.

Aevi Genomic Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for pediatric onset and life-altering diseases in the United States. The company focuses on translating genetic discoveries into novel treatments, utilizing an internal genomics platform and collaborating with the Center for Applied Genomics at The Children's Hospital of Philadelphia. Its lead product candidate, AEVI-002, is an anti-LIGHT monoclonal antibody currently undergoing a Phase Ib clinical trial for severe pediatric onset Crohn’s disease. Additionally, Aevi is developing AEVI-005, a monoclonal antibody in preclinical research for autoimmune pediatric diseases, and is evaluating the anti-seizure properties of AEVI-004 in preclinical models as part of the National Institutes of Health Epilepsy Treatment Screening Program. Founded in 2000 and based in Wayne, Pennsylvania, the company was previously known as Medgenics, Inc. before rebranding in December 2016.

Haystack Informatics, spun out from Children's Hospital of Philadelphia, is a digital health company that helps leading health systems monitor patient privacy and improve operational efficiency. Using activity log data from electronic health records (EHR) systems, our technology makes sense of the interactions that exist between health system employees and patients, identifying anomalous activity patterns and guiding towards the most impactful areas for EHR and staff optimization.

Velano Vascular, Inc. is a medical device company based in San Francisco, California, that specializes in manufacturing needle-free vascular access devices designed for blood collection. Its flagship product, PIVO, is a sterile, single-use device that allows healthcare providers to draw blood from indwelling peripheral IV lines, thereby minimizing the need for needle sticks and central line access. This innovation aims to reduce the stress and anxiety often associated with blood draws for hospitalized patients while enhancing safety and efficiency for healthcare providers. Founded by a patient and a physician in 2011, Velano Vascular is supported by investors such as First Round Capital, Kapor Capital, and White Owl Capital, and collaborates with prominent U.S. hospital systems focused on patient-centered care.

Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.

Spark Therapeutics, Inc. is dedicated to developing gene therapy products aimed at treating debilitating genetic diseases. The company is known for LUXTURNA, a treatment for patients with biallelic RPE65 mutation-associated retinal dystrophy, and has an extensive pipeline that includes candidates like SPK-8011 and SPK-8016 for hemophilia, SPK-7001 for choroideremia, and SPK-9001 for hemophilia B. Additionally, Spark is exploring liver-directed gene therapies such as SPK-3006 for Pompe disease and has programs targeting neurodegenerative diseases, including Huntington's disease and a form of Batten disease. Spark Therapeutics also engages in collaborations, notably with Pfizer for the SPK-FIX program for hemophilia B, and has a licensing agreement with Novartis for the commercialization of LUXTURNA outside the United States. Established in 2013 and based in Philadelphia, Spark Therapeutics operates as a subsidiary of Roche Holding AG and leverages a proprietary manufacturing platform to support its clinical studies across various therapeutic areas.